Please login to the form below

Deal Watch table for June 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during June 2013.

For an indepth analysis of these deals, read 'Pharma deals during June 2013'

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Pfizer (Wyeth) + Takeda / Teva + Sun Pharmaceutical	Patent settlement	Infringement of Protonix patent	2,150
Pearl Therapeutics / AstraZeneca	Acquisition	Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III)	1,150
Conceptus / Bayer	Acquisition	Bayer acquires >90 per cent shares includes the product Essure, for non-surgical permanent birth control (marketed)	1,100
Merck / Aspen	Acquisition	Aspen acquires Merck drugs/ manufacturing business	1,000
Aragon Pharmaceuticals / J&J	Acquisition	Includes ARN 509 (second generation androgen receptor signalling inhibitor) for castration-resistant prostate cancer (phase II)	1,000
MorphoSys / Celgene	Strategic collaboration	Joint development and co-promotion of MOR 202 in multiple myeloma (phase I/II)	818
CytomX / Pfizer	Collaboration and exclusive licence to selected PDCs	Collaboration for Probody Drug conjugates (PDCs) in oncology (platform)	635
MorphoSys / GSK	Licence to develop and commercialise	MOR 103 (HuCA-derived MAb against GM-CSF), for mild to moderate RA (phase I/II)	580
Seattle Genetics / Bayer HealthCare	Collaboration for development and commmercialisation	Auristatin based antibody-drug conjugate (ADC) technology for certain oncology targets (platform)	520
Cytokinetics / Astellas	Exclusive licence to develop and commercialise	Collaboration for therapies associated with muscle weakness and rights to CK 2127107 (phase I) for certain indications;	490
Immunocore / Genentech	Research collaboration and licence	Discovery and development of multiple targets using Immunocore's ImmTAC technology (platform)	320+
Medicines360 / Actavis*	Licence	US commercial rights to LNG20 Intrauterine Device (IUD) (phase III)	175
MicroDose Therapeutx / Teva	Acquisition	Acquisition of inhalation technology including MDT-637 for RSV (phase II)	165
Novartis / Questcor*	Development rights	Rights to develop Synacthen (tetracosactide, melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune & inflammatory conditions)	135
Fera / Perrigo	Product portfolio acquisition	Ophthalmic sterile ointment and solution product portfolio	129
Cytokinetics / Amgen**	Extension of existing licence to Japan	Small molecules to activate heart muscle, including omecamtiv mecarbil (phase II)	75
Taiwan Liposome Company / SciClone Pharmaceuticals***	Exclusive licence	Commercialisation of ProFlow (lipid emulsion-based formulation of alprostadil) for peripheral arterial disease (approved Taiwan)	39.5
BioLineRx / Jiangsu Chia-tai Tianqing Pharmaceutical (CTTQ)†	Collaboration and licence	BL8030, second generation protease inhibitor in development for Hepatitis C (preclinical)	30
Isconova / Novavax	Acquisition	Proprietary vaccine adjuvant technology	30